GET DAILY SIGNALSICON plc (ICLR) Delivers Record Backlog and Strong Bookings in Q3 Despite Margin Pressure
Key Takeaways
- ICON plc reported third-quarter 2026 revenue of $2,024.8 million, down 2.9% year over year but ahead of the roughly $2.01 billion consensus estimate.
- Adjusted diluted EPS came in at $2.66, above the consensus estimate of roughly $2.62–$2.64 and up 3.9% sequentially.
- Net business wins reached $3,150 million with a book-to-bill ratio of 1.56x, lifting closing backlog to a record $24.5 billion.
- Adjusted EBITDA was $336.9 million, or 16.6% of revenue, down 13.1% year over year on continued margin pressure.
- The company updated full-year 2026 guidance, now targeting revenue of $8,100–$8,200 million and adjusted diluted EPS of $10.35–$10.65.
- ICON repurchased $400 million of stock in the quarter and increased its buyback authorization to $750 million.
Why These Results Matter for Investors
ICON plc (ICLR) stands as a leading clinical research organization that supports pharmaceutical, biotechnology, and medical device firms through clinical trials from early stages to market launch. Its quarterly performance serves as a useful indicator of R&D spending trends in the life-sciences sector. This particular report arrives at a time when demand for outsourced clinical work has been recovering, even while higher pass-through costs and competitive pricing continue to weigh on margins. From what I see, the numbers give investors a clear view on whether the company can maintain its commercial strength while working to restore profitability ahead of 2027.
Quarterly Results in Detail
For the third quarter ended September 30, 2026, revenue totaled $2,024.8 million, representing a 2.9% decline from the same period last year, or 2.5% on a constant-currency basis. That figure still exceeded the consensus estimate of about $2.01 billion. GAAP net income reached $122.1 million, or $1.58 per diluted share, compared with a loss of $(3.67) per diluted share a year earlier that reflected goodwill and asset impairments.
Adjusted diluted EPS came in at $2.66, beating the consensus range of roughly $2.62–$2.64 and rising 3.9% from the prior quarter. Adjusted net income was $205.8 million. Adjusted EBITDA stood at $336.9 million for a margin of 16.6%, down 13.1% year over year. The margin contraction stems from elevated pass-through activity and shifts in business mix that have affected profitability even as top-line and booking metrics stayed solid. I also checked this using Tickeron’s AI Screener to compare the stock’s performance against peers in the healthcare services space.
Commercial momentum remained positive. Gross bookings increased 26.9% year over year to $3,789 million. After cancellations of $639 million, net business wins totaled $3,150 million, producing a book-to-bill ratio of 1.56x. Closing backlog climbed to $24.5 billion, up 4.8% sequentially. Free cash flow for the quarter was $302.4 million.
Market Reaction and Sentiment
Investor response has reflected the contrast between robust bookings and ongoing margin compression. The earnings beat on revenue and adjusted EPS, together with the record backlog and expanded buyback authorization, offered support. At the same time, the year-over-year drop in adjusted EBITDA and the tempered full-year margin outlook have kept sentiment somewhat cautious as investors assess whether pass-through activity and mix shifts will continue to limit profitability. The stock has often reacted to guidance updates and book-to-bill trends, so the revised full-year range and margin commentary stand out as important variables.
Looking Ahead: Guidance and Key Areas to Watch
Updated full-year 2026 guidance calls for revenue between $8,100 million and $8,200 million and adjusted diluted EPS of $10.35–$10.65. Management expressed confidence in delivering revenue growth and earnings improvement in 2027 and beyond, aided by an AI-enabled digital platform that clients have highlighted for improving productivity.
Several factors deserve close attention going forward. The path of adjusted EBITDA margins will be central, as stabilization in pass-through activity and business-mix improvement will determine whether profitability can move back toward earlier levels. Backlog conversion and the durability of the 1.56x book-to-bill ratio will signal whether demand momentum holds into 2027. Capital allocation also remains relevant after $400 million in repurchases and the increase in authorization to $750 million, alongside the $2.15 billion bond issuance for debt refinancing. Broader industry conditions, including biotech funding and pharmaceutical R&D trends, will continue to shape award activity. These elements are likely to influence how the market values the company over the next several quarters.
Enhancing Research with AI Tools
I’ve found Tickeron’s AI Screener particularly useful when analyzing companies like this one. It lets me quickly filter stocks by industry, fundamentals, technical patterns, and AI signals, which helps surface relevant comparisons without spending hours on manual work. The tool has become a regular part of my process for evaluating clinical research and healthcare names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ICLR's Stochastic Oscillator stays in overbought zone for 3 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ICLR moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 21 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICLR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
ICLR broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ICLR as a result. In 63 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
The Moving Average Convergence Divergence (MACD) for ICLR just turned positive on October 15, 2026. Looking at past instances where ICLR's MACD turned positive, the stock continued to rise in 31 of 43 cases over the following month. The odds of a continued upward trend are 72%.
ICLR moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ICLR crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Following a +6.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICLR advanced for three days, in 202 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 140 of 220 cases where ICLR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ICLR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.512) is normal, around the industry mean (65.624). ICLR's P/E Ratio (274.298) is considerably higher than the industry average of (2.414). Projected Growth (PEG Ratio) (0.533) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.626) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICLR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of clinical research and development services
Industry MedicalSpecialties
Advertisement